In the rapidly evolving landscape of drug discovery, Proteolysis-Targeting Chimeras (PROTACs) have emerged as a paradigm-shifting modality. By harnessing the cell’s natural waste disposal system—the ubiquitin-proteasome pathway—to selectively degrade disease-causing proteins, PROTACs offer a therapeutic reach far beyond the limitations of traditional small-molecule inhibitors. Now, the journal Epigenomics is spearheading a critical inquiry into this field, announcing a new Article Collection dedicated to the “Promises and Challenges in the Development of Proteolysis-Targeting Chimeras for Chromatin Modifiers.”
This initiative, spearheaded by Taylor & Francis and guided by esteemed researchers from the National Cancer Institute (NCI), seeks to synthesize the latest advancements in chemical biology, proteomics, and functional genomics to unlock the full potential of targeted protein degradation (TPD) within the complex environment of the cell nucleus.
Main Facts: The Frontier of Targeted Protein Degradation
The core objective of the Epigenomics Article Collection is to move beyond the "proof-of-concept" phase of PROTAC research and address the technical hurdles that have historically hindered the clinical application of these molecules, particularly when targeting nuclear chromatin complexes.
The Mechanics of the PROTAC
At its simplest, a PROTAC is a bifunctional molecule consisting of two chemical entities connected by a linker: one end binds to a target protein, while the other recruits an E3 ubiquitin ligase. This "proximity-inducing" event leads to the polyubiquitination of the target protein, marking it for degradation by the 26S proteasome. Unlike traditional inhibitors, which require high-affinity binding to a specific active site, PROTACs require only transient binding to initiate degradation, potentially opening up "undruggable" targets.
The Nuclear Challenge
Targeting chromatin modifiers—proteins that regulate gene expression through DNA packaging—presents a unique set of challenges. These proteins often reside in the dense, tightly regulated environment of the nucleus, creating significant barriers to drug design. The upcoming collection will focus on:
- Selectivity and Efficacy: Developing strategies to ensure the PROTAC only acts on the intended chromatin modifier without off-target effects.
- Cellular Permeability: Enhancing the ability of these complex, often large molecules to cross the nuclear membrane.
- The "Hook Effect": Addressing the bell-shaped dose-response curve where high concentrations of PROTACs paradoxically inhibit degradation by saturating both the target and the E3 ligase independently.
- Tissue-Specific Degradation: Exploring mechanisms to restrict protein depletion to specific disease-relevant tissues, minimizing systemic toxicity.
Chronology: The Evolution of TPD Research
The journey toward this specialized collection is rooted in over two decades of chemical biology evolution.
- 2001: The Conceptual Birth. The landmark paper by Sakamoto et al. introduces the first bifunctional molecule capable of inducing the degradation of methionine aminopeptidase-2 (MetAP-2), providing the initial framework for PROTACs.
- 2010–2015: Refinement of the "Linker" Logic. Research groups, most notably those led by Craig Crews, refine the design of PROTACs, shifting from peptide-based recruiters to small-molecule E3 ligase ligands, significantly improving cellular permeability.
- 2019: Clinical Validation. The first PROTACs enter human clinical trials, signaling the shift from academic curiosity to a robust pharmaceutical pipeline.
- 2023–2024: The Epigenetic Focus. As the field matures, attention shifts toward the highly regulated proteins of the epigenome. The community identifies chromatin modifiers as "high-value, high-difficulty" targets, leading to the call for this focused Epigenomics collection.
- 2025 (Upcoming): The Call for Submissions. Epigenomics opens its doors to contributions that define the next generation of chromatin-targeted therapies.
Supporting Data: Why Chromatin Modifiers?
Chromatin modifiers—including histone methyltransferases, acetyltransferases, and deacetylases—are central to cancer biology. Dysregulation of these enzymes is a hallmark of numerous malignancies, including hematologic cancers and solid tumors.
Current data suggests that traditional "occupancy-based" inhibition is often insufficient to fully suppress the functional output of these complexes. Because chromatin modifiers often function within large, protein-dense complexes, removing the protein entirely via degradation (rather than simply blocking an active site) provides a more profound therapeutic effect.
Recent studies published in journals like Nature Chemical Biology have shown that PROTACs can lead to "deeper" biological responses in models of acute myeloid leukemia (AML) compared to traditional small-molecule inhibitors. The challenge, as highlighted by the Epigenomics team, is the translation of these findings into clinical stability and pharmacological safety. The upcoming collection intends to collate the data-driven evidence that validates whether this technology can overcome the resistance mechanisms that often render conventional epigenetic drugs ineffective over time.
Official Responses and Expert Perspectives
The partnership between Epigenomics and the National Cancer Institute (NCI) underscores the clinical urgency of this work. Guest Advisers Dr. Vassiliki Saloura and Dr. William J. Moore, both of the NCI’s Center for Cancer Research, are instrumental in defining the scope of this collection.
In early communications regarding the initiative, Dr. Saloura and Dr. Moore emphasized that the field is at a "critical juncture." They noted:
"While the potential for PROTACs in oncology is undeniable, the complexity of nuclear chromatin regulation requires a more nuanced approach than the current standard-of-care. By pooling expertise from chemists, structural biologists, and oncologists, we aim to establish a definitive reference point for the future of epigenetic therapeutics."
George Leung, the Commissioning Editor at Taylor & Francis, has highlighted the strategic value of the Article Collection format:
"Our goal is to create more than just a list of papers. We are building a key resource that serves as a lighthouse for the research community. When articles are published together in a themed collection, they receive higher visibility, increased engagement from social media channels, and, crucially, a higher likelihood of being cited. This synergy accelerates the pace of discovery for every participant."
Implications: The Future of Precision Medicine
The implications of successfully deploying PROTACs against chromatin modifiers are vast. If researchers can master the degradation of these proteins, the clinical impact could extend far beyond oncology into immunology, neurodegeneration, and metabolic disease.
Redefining "Druggability"
Perhaps the most significant implication is the expansion of the "druggable proteome." Many chromatin modifiers have been classified as "undruggable" due to their lack of deep, defined catalytic pockets. PROTACs bypass the need for a pocket, requiring only a surface binding site. This effectively triples the number of potential drug targets available to the pharmaceutical industry.
The Synergistic Effect of the Collection
By concentrating the latest research in one location, the Epigenomics collection will serve as a catalyst for collaboration. It provides a platform for:
- Standardization: Establishing common benchmarks for how PROTAC efficacy and selectivity should be measured.
- Cross-Disciplinary Dialogue: Forcing a collision between the worlds of synthetic chemistry and epigenetic functional genomics.
- Accelerated Bench-to-Bedside Transition: By highlighting the most innovative solutions to the "hook effect" and permeability, the collection provides a roadmap for industrial drug development.
A Call to the Scientific Community
As the scientific community turns its gaze toward the next wave of precision medicine, the invitation from Epigenomics serves as a clarion call. Researchers working on the intersection of chemical biology and epigenetic regulation are invited to submit their findings.
Whether an author is presenting a novel E3 ligase ligand, a new strategy for improving cellular uptake, or a comprehensive review of clinical-stage chromatin degraders, the Epigenomics Article Collection offers a unique opportunity to contribute to a field that is currently redefining the possibilities of medicine.
For those interested in contributing, inquiries should be directed to George Leung, the Commissioning Editor. As the landscape of epigenetic therapy continues to shift, this collection stands poised to capture the moment when PROTAC technology moves from an experimental concept to a cornerstone of modern pharmacological intervention.
How to Participate
The call for submissions is now open. Potential contributors are encouraged to review the full scope of the Epigenomics journal and the specific themes of the Article Collection. By engaging with this collection, researchers are not merely publishing an article—they are contributing to the foundational literature of a new era in molecular medicine.
For further details, researchers can visit the official Taylor & Francis information page to explore the submission guidelines and the full vision for this initiative.
About the Author
